RCMNY
FOLD

Rubric Capital Management (New York)’s Amicus Therapeutics FOLD Stock Holding History

Rubric Capital Management (New York)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-365,000
Closed -$4.55M – 66
2019
Q2 		$4.55M Hold
365,000
– – 0.36% 44
2019
Q1 		$4.96M Buy
+365,000
New +$4.46M 0.46% 49

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Rubric Capital Management (New York)'s FOLD Position: Q3 2019 in Review

Rubric Capital Management (New York) sold out of Amicus Therapeutics (FOLD) in Q3 2019, closing a stake of 365,000 shares — an estimated $4.55M sold.

Rubric Capital Management (New York) first reported a position in FOLD in Q1 2019 and held it in 2 quarters. The position peaked at $4.96M in Q1 2019. 205 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

  • Rubric Capital Management (New York) reported no remaining Amicus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 365,000 Amicus Therapeutics shares in Q3 2019, an estimated $4.55M.
  • Rubric Capital Management (New York) first reported a position in Amicus Therapeutics in Q1 2019 and held it in 2 quarters.
  • Rubric Capital Management (New York)'s Amicus Therapeutics position peaked at $4.96M in Q1 2019.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2019, filed 14 Nov 2019.